Modulation of thymosin beta-4 in skin
US8632827B2 · kind B2 · utility
0Cited by
3References
1Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 13, 2011 |
| Grant date | Jan 21, 2014 |
| Priority date | — |
| Expiry date | Dec 13, 2031 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12Q1/68
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Methods for preventing, ameliorating, or reducing dermatological signs of aging are provided which employ active agents, other than a retinoid, that stimulate thymosin beta-4 expression in the skin. Also provided are methods for screening for substances which stimulate thymosin beta-4 expression levels and the methods of using active agents identified by the screening protocol in the treatment of skin.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.